ibs
The findings highlight TnAse producing gut microbiota, indole, and AhR as promising therapeutic targets for IBS-associated affective disturbances.
Giovanni Barbara (University of Bologna), Congress Chair, reflects on the key takeaways from the congress and shares his closing remarks.
The fifth edition of IBS Days, a congress entirely dedicated to Irritable Bowel Syndrome, will take place in Bologna, Italy, from June 15 to 17, 2026.
William Fusco, gastroenterologist at Policlinico Universitario Agostino Gemelli, highlighted a recently published pilot study on post-infectious irritable bowel syndrome (IBS) framed within microbial precision medicine and biomarker-driven care.
Researchers have found that certain gut bacteria and their metabolites differ between IBS subtypes.
Understanding the complex interactions between exercise, diet and gut health can help to develop approaches to influence the gut microbiota, boost immunity and prevent or manage gastrointestinal diseases.
Launching a new frontier in IBS management: the 'TrIuMPH' trial sets the stage with EBX-102-02, a pioneer in microbiome-based therapy.
Giovanni Barbara, congress chair, explain why it is important to be part of IBS Days 2024.
According to the authors, results suggest that patients with a specific microbial signature have a more favorable response to therapy.
The gut microbiota can be useful to distinguish between IBD and IBS. That's according to a study published in Science Translational Medicine.
